2023
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas
Offin M, Fitzgerald B, Zauderer M, Doroshow D. The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas. Journal Of Cancer Metastasis And Treatment 2023, 9: null-null. PMID: 38895597, PMCID: PMC11185317, DOI: 10.20517/2394-4722.2022.140.Peer-Reviewed Original ResearchDiffuse pleural mesotheliomaPleural mesotheliomaClinical trialsAvailability of preclinical modelsSuppressor T cell activityRefining patient selection criteriaWilms' tumor 1 proteinBRCA1-associated protein 1Vascular endothelial growth factorT cell activationPatient selection criteriaTargeted therapeutic strategiesEndothelial growth factorTargeted therapeutic approachesClinically relevant biomarkersArgininosuccinate synthetase 1Preclinical dataTargeted therapyPreclinical modelsMethylthioadenosine phosphorylaseTherapeutic strategiesTherapeutic approachesRelevant biomarkersGrowth factorGenomic landscape
2017
BET inhibitors: a novel epigenetic approach
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Annals Of Oncology 2017, 28: 1776-1787. PMID: 28838216, DOI: 10.1093/annonc/mdx157.Peer-Reviewed Original ResearchConceptsBET inhibitorsHDAC inhibitorsEpigenetic agentsExtra-terminal motif (BET) proteinsImmune checkpoint inhibitorsEarly clinical trialsNovel epigenetic approachHistone deacetylaseZeste homolog 2BET proteinsMonotherapy activityCheckpoint inhibitorsTargeted agentsPreclinical dataClinical trialsDrug classesDrug combinationsSingle agentSolid tumorsPreclinical researchTumor cellsHomolog 2Lysine-specific demethylase 1Anticancer therapyInhibitors